Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate Approach

Dual activation of the TLR7 and TLR8 pathways leads to the production of type I interferon and proinflammatory cytokines, resulting in efficient antigen presentation by dendritic cells to promote T-cell priming and antitumor immunity. We developed a novel series of TLR7/8 dual agonists with varying ratios of TLR7 and TLR8 activity for use as payloads for an antibody-drug conjugate approach. The agonist-induced production of several cytokines in human whole blood confirmed their functional activity. Structure-activity relationship studies guided by structure-based drug design are described.

Authors

Institutions

Publication Details

Journal
ACS Medicinal Chemistry Letters
Published
2024-12-19
DOI
https://doi.org/10.1021/acsmedchemlett.4c00463
Citations
3
Primary Topic
Immune Response and Inflammation
Type
article
Field-Weighted Citation Impact
0.72
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate Approach

Yam B. Poudel, Ashvinikumar V. Gavai, David Critton, Payal Dhar et al.
3 citations
ACS Medicinal Chemistry Letters
Immune Response and Inflammation
0.72
article

Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate Approach

Yam B. Poudel, Ashvinikumar V. Gavai, David Critton, Payal Dhar, Lakshumanan Subramani, Arvind Mathur, Chunshan Xie, Derek Norris, Emanuela Sega, Dahlia R. Weiss, Dawn Mulligan, Shaily Jain, Julian C. Lo, Sayumi Yamazoe, Christoph W. Zapf, Soodamani Thangavel, Prasanna Sivaprakasam, Murugaiah A. M. Subbaiah, Yvonne Li, Liqi He, Matthew Cox, Eugene P. Chekler, Maheswara Reddy, Walter L. Johnson, Santigopal Mondal
article en
3 citations

Abstract

Dual activation of the TLR7 and TLR8 pathways leads to the production of type I interferon and proinflammatory cytokines, resulting in efficient antigen presentation by dendritic cells to promote T-cell priming and antitumor immunity. We developed a novel series of TLR7/8 dual agonists with varying ratios of TLR7 and TLR8 activity for use as payloads for an antibody-drug conjugate approach. The agonist-induced production of several cytokines in human whole blood confirmed their functional activity. Structure-activity relationship studies guided by structure-based drug design are described.

ACS Medicinal Chemistry LettersVol. 16(1)
Bristol-Myers Squibb (United States) (US), Bristol-Myers Squibb (India) (IN), Biocon (India) (IN)
Zero hunger
Openalex Percentile: Top 27%
Immune Response and Inflammation
0.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.